Novartis Venture Fund

United States
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program. We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates.
Founded:1996
Firm Location:United States • Cambridge, Massachusetts • Basel, Switzerland
Novartis Venture Fund Team
Photo of Laura Brass, Managing Director at Novartis Venture Fund
Laura Brass
Novartis Venture Fund·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Cambridge (MA)
Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Boston / New England (Other Lists), Investors in BioTech (Seed)
Photo of Anja Konig, Managing Director at Novartis Venture Fund
Anja Konig
Novartis Venture Fund·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Basel (Switzerland)
Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Series A)
Photo of Florian Müllershausen, Managing Director at Novartis Venture Fund
Florian Müllershausen
Novartis Venture Fund·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Basel (Switzerland)
Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A)
Photo of Nandita Shangari, Managing Director at Novartis Venture Fund
Nandita Shangari
Novartis Venture Fund·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Cambridge (MA)
Investors in Digital Health (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in Digital Health (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Boston / New England (Other Lists)
Photo of Beat Steffen, Managing Director at Novartis Venture Fund
Beat Steffen
Novartis Venture Fund·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Basel (Switzerland)
Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A)